Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 12:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 498 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Sponsor: Ohio State University Comprehensive Cancer Center Clear all
Completed Phase 2 Interventional Results available

OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer

NCT00230126
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
erlotinib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Sep 26, 2026, 12:23 PM EDT
Completed Not applicable Interventional

Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma Patients

NCT01653106
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
cryotherapy, questionnaire administration, pharmacological study
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 26, 2026, 12:23 PM EDT
Completed No phase listed Observational

Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Non-Small Cell Lung Cancer And Bronchial Disease

NCT00754910
View directory record Official record
Conditions
Lung Cancer
Interventions
porfimer sodium, bronchoscopy
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 26, 2026, 12:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Black Raspberry Phytochemicals on Oral Microbiome in Current Smokers and Non-smokers

NCT02439255
View directory record Official record
Conditions
Healthy Subject, Tobacco Use Disorder
Interventions
Laboratory Biomarker Analysis, Phytochemical, Placebo, Screening Questionnaire Administration
Other · Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 50 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 4, 2022 · Synced Sep 26, 2026, 12:23 PM EDT
Completed Not applicable Interventional

Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer

NCT01764789
View directory record Official record
Conditions
Anxiety Disorder, Depression, Fatigue, Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pain, Peritoneal Carcinomatosis, Pseudomyxoma Peritonei, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Gestational Trophoblastic Tumor, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
Interventions
questionnaire administration, quality-of-life assessment, psychosocial assessment and care, behavioral intervention, cognitive intervention, educational intervention
Other · Procedure · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years to 85 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2015 · Synced Sep 26, 2026, 12:23 PM EDT
Completed No phase listed Observational

Comprehensive Gene Sequencing in Guiding Treatment Recommendations Patients With Metastatic or Recurrent Solid Tumors

NCT01987726
View directory record Official record
Conditions
Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Breast Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
cytology specimen collection procedure, laboratory biomarker analysis
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 26, 2026, 12:23 PM EDT
Completed Not applicable Interventional Results available

Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)

NCT01640340
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
aprepitant, palonosetron hydrochloride, ondansetron, dexamethasone
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 88 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 6, 2013 · Synced Sep 26, 2026, 12:23 PM EDT
Completed Phase 1 Interventional

Decitabine, Donor Natural Killer Cells, and Aldesleukin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT02316964
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions
decitabine, natural killer cell therapy, aldesleukin, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
Sumithira Vasu
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Sep 26, 2026, 12:23 PM EDT
Completed Phase 1 Interventional

Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

NCT00201812
View directory record Official record
Conditions
Tumors
Interventions
Etanercept, Docetaxel, Dexamethasone
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 26, 2026, 12:23 PM EDT
Terminated Not applicable Interventional

Quality of Life of Adults With Diffuse Large B-cell Lymphoma Treated With Tisagenlecleucel

NCT05199961
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse
Interventions
Digital Health Coaching
Behavioral
Lead sponsor
Pack Health
Industry
Eligibility
18 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Sep 26, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab

NCT04312841
View directory record Official record
Conditions
B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Peripheral T-Cell Lymphoma, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, T-Cell Prolymphocytic Leukemia
Interventions
Letermovir
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 26, 2026, 12:23 PM EDT
Completed Phase 1 Interventional

Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

NCT03892044
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Richter Syndrome, Small Lymphocytic Lymphoma, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions
Duvelisib, Nivolumab
Drug · Biological
Lead sponsor
David Bond, MD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 1, 2024 · Synced Sep 26, 2026, 12:23 PM EDT
Recruiting Phase 2 Interventional

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

NCT06263153
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Biospecimen Collection, Computed Tomography, Durvalumab, Futibatinib, Magnetic Resonance Imaging, Radical Cystectomy
Procedure · Biological · Drug
Lead sponsor
Yuanquan Yang
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Ann Arbor, Michigan • Cleveland, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 26, 2026, 12:23 PM EDT
Recruiting No phase listed Observational

Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer

NCT03977402
View directory record Official record
Conditions
Cancer, Cancer Risk
Interventions
Biological specimen collection
Other
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
47,500 participants
Timeline
2016 – 2037
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Sep 26, 2026, 12:23 PM EDT
Recruiting Phase 2 Interventional

Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome

NCT05873712
View directory record Official record
Conditions
Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Transformed B-cell Non-Hodgkin Lymphoma, Refractory Transformed
Interventions
Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Fludarabine, Leukapheresis, Lisocabtagene Maraleucel, Lymph Node Biopsy, Positron Emission Tomography, Zanubrutinib
Procedure · Drug · Biological
Lead sponsor
Aseel Alsouqi
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
New York, New York • Columbus, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 26, 2026, 12:23 PM EDT
Recruiting Phase 2 Interventional

Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia

NCT05417165
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Pneumococcal 20-valent Conjugate Vaccine, Pneumococcal Polyvalent Vaccine
Biological
Lead sponsor
Seema Bhat
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 26, 2026, 12:23 PM EDT
Completed Phase 2 Interventional

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer

NCT00201747
View directory record Official record
Conditions
Esophageal Cancer, Esophagus Cancer, Cancer of Stomach, Stomach Cancer
Interventions
CPT-11, Mitomycin C
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 26, 2026, 12:23 PM EDT
Active, not recruiting Not applicable Interventional

Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma

NCT03656835
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma
Interventions
Molecular Nanotechnology
Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 26, 2026, 12:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

NCT05588453
View directory record Official record
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Natural Killer Cell Therapy, Temozolomide
Biological · Drug
Lead sponsor
Kari Kendra
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 26, 2026, 12:23 PM EDT
Completed Not applicable Interventional

Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen

NCT01682941
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage IV Prostate Cancer
Interventions
Arm I Soy Bread, Arm II Soy-Almond Bread
Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Sep 26, 2026, 12:23 PM EDT
Terminated Phase 2 Interventional Results available

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00754923
View directory record Official record
Conditions
Lung Cancer
Interventions
sorafenib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 26, 2026, 12:23 PM EDT
Completed Not applicable Interventional

Clinical Impact of Enhanced Risk Assessments in Women With a BRCA1/2 Mutation, CARE Study

NCT06534424
View directory record Official record
Conditions
BRCA1/2-Associated Hereditary Breast and Ovarian Cancer Syndrome
Interventions
Best Practice, Biospecimen Collection, Counseling, Discussion, Genotyping, Molecular Risk Assessment, Questionnaire Administration
Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Columbus, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 26, 2025 · Synced Sep 26, 2026, 12:23 PM EDT
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Bioavailability and Pharmacodynamics of EPA and DHA From Fortified Soymilk and Capsules

NCT05802797
View directory record Official record
Conditions
Healthy Diet
Interventions
Algae Oil Fortified Soymilk, Algae Oil Capsule
Other · Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Sep 26, 2026, 12:23 PM EDT
Completed Phase 1 Interventional Results available

Neoadjuvant Chemotherapy IV Carboplatin With Weekly Paclitaxel \Bevacizumab for Primary Ovarian

NCT01219777
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
carboplatin, Bevacizumab, Paclitaxel
Drug
Lead sponsor
Ritu Salani
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2018 · Synced Sep 26, 2026, 12:23 PM EDT